Сравнение
Desmopressin vs. Glepaglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
16679-58-6
нет данных
Молекулярная масса
1069.2 g/mol
нет данных
Период полувыведения
3 h
нет данных
Последовательность
Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (Disulfid 1-6)нет данных
Механизм действия
Desmopressin
Desmopressin is a structurally modified analogue of the nine-residue peptide hormone vasopressin. Deamination at the N-terminus (1-deamino) and replacement of L-arginine by D-arginine at position 8 prolong the duration of action and render the compound largely selective for the vasopressin V2 receptor, while the V1-mediated vasoconstrictive effect is strongly reduced. Acting on V2 receptors in the renal collecting ducts, it promotes insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and reducing urine volume (antidiuretic effect). In addition, via V2 receptors on the vascular endothelium, desmopressin stimulates the release of von Willebrand factor and factor VIII from endothelial stores (Weibel-Palade bodies), improving primary haemostasis.
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
2
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Desmopressin and Glepaglutide?
- Desmopressin is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Desmopressin: Desmopressin (DDAVP) is a synthetic analogue of the endogenous hormone vasopressin (antidiuretic hormone, ADH). Deamination of the first amino acid and substitution of L-arginine with D-arginine give it selective activity at the V2 receptor with strongly reduced pressor (V1) activity. It has been approved for decades for indications including central diabetes insipidus, primary nocturnal enuresis, and bleeding tendency in von Willebrand disease type 1 and mild haemophilia A. The principal safety concern is hyponatremia or water intoxication. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Desmopressin or Glepaglutide?
- The highest available evidence level is "РКИ на людях" for Desmopressin and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Desmopressin and Glepaglutide in Germany and the United States?
- Германия: Desmopressin — Рецептурный, Glepaglutide — Не одобрено. США: Desmopressin — Рецептурный, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.